Abstract
Management of the advanced heart failure patient can be complex. Therapies include cardiac transplantation and mechanical circulatory support, as well inotropic agents for the short-term. Despite a growing armamentarium of resources, the clinician must carefully weigh the risks and benefits of each therapy to develop an optimal treatment strategy. While cardiac transplantation remains the only true “cure” for end-stage disease, this resource is limited and the demand continues to far outpace the supply. For patients who are transplant-ineligible or likely to succumb to their illness prior to transplant, ventricular assist device therapy has now become a viable option for improving morbidity and mortality. Particularly for the non-operative patient, intravenous inotropes can be utilized for symptom control. Regardless of the treatments considered, care of the heart failure patient requires thoughtful dialogue, multidisciplinary collaboration, and individualized care. While survival is important, most patients covet quality of life above all outcomes. An often overlooked component is the patient’s control over the dying process. It is vital that clinicians make goals-of-care discussions a priority when seeing patients with advanced heart failure. The use of palliative care consultation is well-validated and facilitates these difficult conversations to ensure that all patient needs are ultimately met.
Keywords: Cardiac transplantation, end-stage heart failure, inotrope, palliative care, ventricular assist device.
Graphical Abstract
[1]
Stevenson LW, Rose EA. Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom? Circulation 2003; 108: 3059-63.
[2]
Stehlik J, Edwards LB, Kucheryavaya AY, et al. International Society of Heart and Lung Transplantation The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. J Heart Lung Transplant 2012; 31: 1052-64.
[3]
Colvin-Adams M, Smith JM, Heubner BM, et al. OPTN/SRTR 2011 Annual Data Report: heart. Am J Transplant 2013; 13(Suppl. 1): 119-48.
[4]
Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am Coll Cardiol 1993; 22: 21-31.
[5]
Miller LW. Listing criteria for cardiac transplantation: results of an American Society of Transplant Physicians-National Institutes of Health conference. Transplantation 1998; 66: 947-51.
[6]
Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant 2006; 25: 1024-42.
[7]
Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660-7.
[8]
Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-86.
[9]
O’Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005; 111: 2313-8.
[10]
Elmariah S, Goldberg LR, Allen MT, Kao A. Effects of gender on peak oxygen consumption and the timing of cardiac transplantation. J Am Coll Cardiol 2006; 47: 2237-42.
[11]
Osman AF, Mehra MR, Lavie CJ, et al. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. J Am Coll Cardiol 2000; 36: 2126-31.
[12]
Levy WC, Aaronson KD, Dardas TF, Williams P, Haythe J, Mancini D. Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population. J Heart Lung Transplant 2012; 31(8): 817-24.
[14]
Schulze PC, Jiang J, Yang J, et al. Preoperative Assessment of High Risk Candidates to Predict Survival Following Heart Transplantation. Circ Heart Fail 2013; 6: 527-34.
[15]
Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation Guidelines The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-56.
[16]
Mullen JC, Bentley MJ, Scherr KD, et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur J Cardiothorac Surg 2002; 22: 233-7.
[17]
O’Neill JO, McRae AT III, Troughton RW, et al. Brain natriuretic peptide levels do not correlate with acute cellular rejection in De Novo orthotopic heart transplant recipients. J Heart Lung Transplant 2005; 24: 416-20.
[18]
Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587-93.
[19]
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-20.
[20]
Mena C, Wencker D, Krumholz HM, McNamara RL. Detection of heart transplant rejection in adults by echocardiographic diastolic indices: a systematic review of the literature. J Am Soc Echocardiogr 2006; 19: 1295-300.
[21]
Deng MC, Eisen HJ, Mehra MR, et al. for the CARGO Investigators Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6: 150-60.
[22]
Pham MX, Teuteberg JJ, Kfoury AG, et al. IMAGE Study Group Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362: 1890-900.
[23]
Lindenfeld J, Page RL 2nd, Zolty R, et al. Drug therapy in the heart transplant recipient: Part III: common medical problems. Circulation 2005; 111: 113-7.
[24]
Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005; 111: 230-9.
[25]
Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29: 717-27.
[26]
Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164-70.
[27]
Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
[28]
Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002; 359: 1108-13.
[29]
Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954; 37: 171-85.
[30]
Helman DN, Rose EA. History of mechanical circulatory support. Prog Cardiovasc Dis 2000; 43: 1-4.
[31]
Debakey ME. Left ventricular bypass pump for cardiac assistance. Clinical experience. Am J Cardiol 1971; 27: 3-11.
[32]
Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345: 1435-43.
[33]
Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013; 32: 141-56.
[34]
Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support at the time of transplantation. J Am Coll Cardiol 2010; 56: 1207-13.
[35]
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. JACC 2009; 53: e1-e90.
[36]
Thackray S, Easthaughb J, Freemantleb N, Cleland JGF. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta-regression analysis. European Journal of Heart Failure 2002; 4: 515-29.
[37]
Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 2012; 38: 359-67.
[38]
Sindone AP, et al. Continuous Home Ambulatory Intravenous Inotropic Drug Therapy in Severe Heart Failure: Safety and Cost Efficacy. Am Heart J 1997; 134: 889-900.
[39]
Lopez-Candales A, et al. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes. Clin Cardiol 2004; 27: 23-48.
[40]
Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998; 63: 682-5.
[41]
Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138: 247-53.
[42]
Gorodeski ED, Chu EC, Reese JR, et al. Prognosis on Chronic Dobutamine or Milrinone Infusions for Stage D Heart Failure. Circ Heart Fail 2009; 2: 320-4.
[43]
Hauptman PJ, Mikolajczak P, George A, et al. Chronic inotropic therapy in end-stage heart failure. Am Heart J 2006; 152(1096): e121096-8.
[44]
Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. J Am Med Assoc 2008; 299: 2533-42.
[45]
Dev S, Abernethy AP, Rogers JG, O’Connor CM. Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care setting. Am Heart J 2012; 164: 313-19.e5.
[46]
Kini V, Kirkpatrick JN. Ethical challenges in advanced heart failure. Curr Opin Support Palliat Care 2013; 7: 21-8.
[47]
Habal MV, Micevski V, Greenwood S, Delgado DH, Ross HJ. How aware of Advanced Care Directives are Heart Failure Patients, and are they using them? Can J Cardiol 2011; 27: 376-81.
[48]
Lemond L, Allen LA. Palliative Care and Hospice in Advanced Heart Failure. Prog Cardiovasc Dis 2011; 54: 168-78.
[49]
Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative Care in the Treatment of Advanced Heart Failure. Circulation 2009; 120: 2597-606.
[50]
Goldfinger JZ, Adler ED. End-of-life Options for Patients with Advanced Heart Failure. Curr Heart Fail Rep 2010; 7: 140-7.
[51]
Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-96.
[52]
Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-51.
[53]
Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 20012(25): 3191-200.
[54]
Risk assessment and comparative effectiveness of left ventricular
assist device and medical management. ROADMAP. Accessed,
March 1, 2013.
www.clinicaltrials.gov
Identifier # NCT01452802.
[55]
The evaluation of VAD intervention before inotropic therapy.
REVIVE-IT. Accessed, March 1, 2013.
www.clinicaltrials.gov
Identifier # NCT01369407.
[56]
Jarvik 2000 Heart as a bridge to cardiac transplantation – Pivotal
Trial. Accessed April 30, 2013.
www.clinicaltrials.gov
Identifier #
NCT00591799.
Article Metrics
85
3
1
1